Oxytrol For Women is a drug owned by Abbvie. It is protected by 8 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 26, 2020. Details of Oxytrol For Women's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7081249 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) |
Expired
|
| US7179483 | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) |
Expired
|
| US7081250 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) |
Expired
|
| US7081251 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) |
Expired
|
| US6743441 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) |
Expired
|
| US7081252 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) |
Expired
|
| US5834010 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(9 years ago) |
Expired
|
| US5601839 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(9 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Oxytrol For Women's patents.
Latest Legal Activities on Oxytrol For Women's Patents
Given below is the list of recent legal activities going on the following patents of Oxytrol For Women.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Aug, 2018 | US7179483 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jan, 2018 | US7081252 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jan, 2018 | US7081249 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jan, 2018 | US7081250 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jan, 2018 | US7081251 |
| Change in Power of Attorney (May Include Associate POA) Critical | 08 Dec, 2010 | US7081252 |
| Correspondence Address Change Critical | 08 Dec, 2010 | US7081252 |
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Jul, 2010 | US7081250 |
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Jul, 2010 | US7081249 |
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Jul, 2010 | US7081251 |
FDA has granted several exclusivities to Oxytrol For Women. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Oxytrol For Women, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Oxytrol For Women.
Exclusivity Information
Oxytrol For Women holds 1 exclusivities. All of its exclusivities have expired in 2016. Details of Oxytrol For Women's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 25, 2016 |
US patents provide insights into the exclusivity only within the United States, but Oxytrol For Women is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Oxytrol For Women's family patents as well as insights into ongoing legal events on those patents.
Oxytrol For Women's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Oxytrol For Women's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 26, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Oxytrol For Women Generic API suppliers:
Oxybutynin is the generic name for the brand Oxytrol For Women. 1 company has already filed for the generic of Oxytrol For Women. Check out the entire list of companies who have already received approval for Oxytrol For Women's generic
Alternative Brands for Oxytrol For Women
Oxytrol For Women which is used for treating overactive bladder., has several other brand drugs using the same active ingredient (Oxybutynin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Abbvie |
| ||
| Allergan |
| ||
| Janssen Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Oxybutynin, Oxytrol For Women's active ingredient. Check the complete list of approved generic manufacturers for Oxytrol For Women
About Oxytrol For Women
Oxytrol For Women is a drug owned by Abbvie. It is used for treating overactive bladder. Oxytrol For Women uses Oxybutynin as an active ingredient. Oxytrol For Women was launched by Abbvie in 2013.
Approval Date:
Oxytrol For Women was approved by FDA for market use on 25 January, 2013.
Active Ingredient:
Oxytrol For Women uses Oxybutynin as the active ingredient. Check out other Drugs and Companies using Oxybutynin ingredient
Treatment:
Oxytrol For Women is used for treating overactive bladder.
Dosage:
Oxytrol For Women is available in film, extended release form for transdermal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 3.9MG/24HR | FILM, EXTENDED RELEASE | Over the counter | TRANSDERMAL |